Non Hodgkin Lymphoma Clinical Trial
Study Evaluating CMC-544 In B-Cell Non-Hodgkin’s Lymphoma
Summary
To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).
Eligibility Criteria
Inclusion Criteria:
Subjects who have been previously diagnosed with CD22-positive, B-cell NHL, according to WHO classification, which has progressed after at least 2 prior therapies of probable clinical benefit
At the expanded cohort, part 2 of the study, subjects must have one of the following:
Follicular lymphoma previously treated with at least one dose of rituximab, but have not received radioimmunotherapy
Diffuse large B-cell lymphoma
Age 18 years or older
Exclusion Criteria:
Candidate for potentially curative therapies in the opinion of the investigator
Chronic lymphocytic leukemia
Burkitt's lymphoma, primary effusion lymphoma, and precursor B-cell lymphoblastic lymphoma
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 18 Locations for this study
Birmingham Alabama, 35233, United States
Birmingham Alabama, 35233, United States
Birmingham Alabama, 35294, United States
Birmingham Alabama, 35294, United States
Chicago Illinois, 60611, United States
Chicago Illinois, 60611, United States
Buffalo New York, 14263, United States
Cleveland Ohio, 44195, United States
Philadelphia Pennsylvania, 19104, United States
Philadelphia Pennsylvania, 19111, United States
Houston Texas, 77030, United States
Leuven , 3000, Belgium
Paris , 75010, France
Pierre Benite Cedex , 69495, France
Bonn NRW, 53105, Germany
Mainz , 55131, Germany
Muenchen , 81377, Germany
Muenchen , 81377, Germany
Barcelona , 08025, Spain
Barcelona , 08036, Spain
Lausanne , 1011, Switzerland
London , EC1A , United Kingdom
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.